-
Thousands of counties cover 10,000 transmissions, 100 million people scale billion traffic! "Red Boat Leads the Way, Healthy and Powerful Country" China Oncology Conference Science Popularization Tour China is coming
Time of Update: 2023-01-07
Starting from Jiaxing South Lake, the seeds of tumor prevention and treatment were sown in the motherland and took root and germinated This is a journey of "people-centered" original intention At today's press conference, Academician Tan Weihong, academician of the Chinese Academy of Sciences, director of the Institute of Medicine of the Chinese Academy of Sciences, and president of Zhejiang Cancer Hospital, introduced to reporters the activities of the science popularization trip to China.
-
The 2022 International Multi-center Clinical Trial Summit Forum (Jinling Multinational Corporations) is about to begin!
Time of Update: 2023-01-07
Multi-regional Clinical Trials (MRCT) has gradually become an efficient mode for the global simultaneous research and development of new drugs and new medical devices, and more and more multinational
-
Nutritional support for the treatment of cancer patients and between treatments
Time of Update: 2023-01-07
Editor: Traveler Yimaitong edited and sorted, please do not reprint without authorization. In the past half century, malignant tumors have become a common life-threatening disease in China, malnutriti
-
ESMO Reviews Professor Feng Mingxiang: Baseline ctDNA is an independent predictor of postoperative recurrence and has broad clinical application scenarios!
Time of Update: 2023-01-07
In an oral presentation, Professor Myung-Ju Ahn presented a study exploring longitudinal monitoring of ctDNA in patients with resectable stage IA-IIIA EGFR-mutated non-small cell lung cancer (NSCLC) in order to predict the prognosis of these patients.
-
2022 CSCO |Professor Jiang Zefei: CSCO Academic Week kicked off in Beijing, focusing on cutting-edge progress and sharing academic feasts
Time of Update: 2023-01-06
Yimaitong: The academic week of this year's CSCO Annual Conference was held in the mode of "online + offline", which not only brought together the progress of multi-tumor diagnosis and treatment, but also focused on innovative tumor drugs, artificial intelligence, patient education and other fields, and discussed the clinical frontier of tumor in all aspects and dimensions.
-
The 2022 CSCO | was full of wonderful and colorful flowers, and the special session on innovative drug clinical research data was held in Beijing
Time of Update: 2023-01-06
7. Professor Shi Yuankai: Phase II clinical study of Iruac (WX-0593) in the treatment of crizotinib-resistant/unused ROS1-positive non-small cell lung cancer patients with crizotinib This is an open-label, non-randomized, single-arm, multicenter, phase II clinical trial with primary endpoints of IRC-assessed ORR, and secondary endpoints including investigator-assessed ORR, DoR, DCR, PRF, TTP, intracranial objective response rate, OS, and adverse events.
-
The 2022 CSCO | was full of wonderful and colorful flowers, and the special session on innovative drug clinical research data was held in Beijing
Time of Update: 2023-01-06
7. Professor Shi Yuankai: Phase II clinical study of Iruac (WX-0593) in the treatment of crizotinib-resistant/unused ROS1-positive non-small cell lung cancer patients with crizotinib This is an open-label, non-randomized, single-arm, multicenter, phase II clinical trial with primary endpoints of IRC-assessed ORR, and secondary endpoints including investigator-assessed ORR, DoR, DCR, PRF, TTP, intracranial objective response rate, OS, and adverse events.
-
A case-control study of antimicrobials and glioma risk
Time of Update: 2023-01-06
of the Department of Neurology at the University Hospital Regensburg, Germany, conducted a case-control study based on a large and validated database to explore the relationship between antimicrobial use and glioma risk.
-
Precise innovation, wisdom and humanities Bearing the 25th anniversary of ups and downs, the 2022 CSCO Annual Meeting was grandly opened in Beijing!
Time of Update: 2023-01-06
The 25th National Congress of Clinical Oncology and the 2022 Chinese Society of Clinical Oncology Annual Conference officially kicked off in Beijing today, and the conference was held in the form of "
-
TRAP research opens up new ideas, and big coffee gathers to discuss colorectal cancer targets and the present and the future
Time of Update: 2023-01-06
At this ESMO conference, the preliminary results of the TRAP study of tyrosine kinase inhibitor (TKI) combined with PD-1 inhibitor in the treatment of microsatellite stability or mismatch repair normal (MSS/pMMR) metastatic colorectal adenocarcinoma in the treatment of TKI response by the team of Professor Zhang Jingdong of Liaoning Provincial Cancer Hospital brought new ideas to TKI combined immunotherapy.
-
Focusing on Exploration, Exploration and Innovation China's Innovation, New Options for Anti-HER2 Treatment - The 2022 CSCO Annual Meeting Septin ® Satellite Meeting was successfully held
Time of Update: 2023-01-06
Professor Wang Shusen briefly summarized the first chapter: Professor Chen Wenyan started from the treatment strategy of advanced HER2-positive breast cancer, from the arrangement of first-line, second-line and posterior drugs and the latest research trends of clinical drugs, macromolecular monoclonal antibody H drugs are the cornerstone of anti-HER2 treatment, while small molecule TKI and the latest ADC drugs are also leading the way, which is worth looking forward to!
-
CSCO's first live broadcast room | upper gastrointestinal system tumors ushered in an immunotherapy feast
Time of Update: 2023-01-06
Figure 1: OS, PFS, ORR, and duration of response (DOR) in PD-L1 CPS≥5 and all randomized populations in nivolumab plus chemotherapy versus chemotherapy Immunotherapy is also gaining momentum in the field of esophageal cancer, and a number of advanced first-line phase III clinical studies have been published, consolidating the position of immunotherapy combined with chemotherapy in the first-line treatment of esophageal cancer.
-
Iron death in gliomas can induce immunotherapy resistance
Time of Update: 2023-01-06
Professor Wu Anhua of the Department of Neurosurgery of the First Affiliated Hospital of China Medical University and other studies have determined that ferrozosis is the most common PCD among gliomas, and is highly correlated with malignant progression, low survival rate and immunotherapy resistance of gliomas.
-
Biomimetic nanoparticles and efficient metabolic synergistic targeting for glioblastoma
Time of Update: 2023-01-06
Professor Li Weiping of the Department of Neurosurgery of the First Affiliated Hospital of Shenzhen University and others developed biomimetic nanomaterials based on the changes in lactate metabolism
-
Biomimetic nanoparticles and efficient metabolic synergistic targeting for glioblastoma
Time of Update: 2023-01-06
Professor Li Weiping of the Department of Neurosurgery of the First Affiliated Hospital of Shenzhen University and others developed biomimetic nanomaterials based on the changes in lactate metabolism
-
When discussing the "three perfections" of tumor immunotherapy in the upper gastrointestinal system
Time of Update: 2023-01-06
Nivolumab in combination with chemotherapy continued the excellent performance in the CheckMate-649 study, with OS benefit observed in all populations; At the same time, the OS benefit was not limited by PD-L1 expression in all randomized patients3 In addition, postoperative adjuvant therapy for esophageal cancer has lacked large-scale clinical research data, and the effect of postoperative traditional chemotherapy is not good.
-
2022 CSCO Professor Liang Jun talked about the development process and future prospects of systemic treatment of liver cancer
Time of Update: 2023-01-06
Professor Liang Jun: Systematic treatment is an indispensable part of multidisciplinary diagnosis and treatment of liver cancer, and the survival of liver cancer patients in the early chemotherapy era is generally poor, and later the application of tyrosine kinase inhibitors (TKI) such as sorafenib, lenvatinib and donafenib has opened up a new era for the systematic treatment of liver cancer.
-
TRAP research opens up new ideas, and big coffee gathers to discuss colorectal cancer targets and the present and the future
Time of Update: 2023-01-06
At this ESMO conference, the preliminary results of the TRAP study of tyrosine kinase inhibitor (TKI) combined with PD-1 inhibitor in the treatment of microsatellite stability or mismatch repair normal (MSS/pMMR) metastatic colorectal adenocarcinoma in the treatment of TKI response by the team of Professor Zhang Jingdong of Liaoning Provincial Cancer Hospital brought new ideas to TKI combined immunotherapy.
-
Olaparib in combination with temozolomide for glioma
Time of Update: 2023-01-06
[Epub ahead of print] 】 Research background Glioma is a common intracranial malignancy that can be avoided after treatment.
In summary, this study analyzes the efficacy and complications of olaparib + TMZ combination in glioma patients, laying a foundation for further clinical trials.
-
International Frontier, Normative Leading HCC International Frontier and Norm Summit Forum was successfully held
Time of Update: 2023-01-06
Chapter 2: Normative Guidance Professor Cui Zilin of Tianjin First Central Hospital reviewed the initial exploration of atezolizumab and bevacizumab in the theme report "Past, present and future of systematic treatment of advanced liver cancer", sorted out the course of atezolizumab + bevacizumab (T+A protocol) in the collaborative fight against HCC, and shared a series of exploratory research new progress, describing the future of atezolizumab + bevacizumab, including MO42541, TALENTACE, IMbrave 050, ABC-HCC and TALENTOP studies, among others.
